... and it’s not the first time

CANADIAN drug firm Concordia is no stranger to accusations of price hiking.

In May last year, reports emerged of it raising the cost of generic medicines supplied to the NHS.

This included a 14-fold rise in the cost of eye drops for bacterial conjunctivitis, for which it was the sole manufacturer.

In October 2016, CEO Mark Thompson, who founded the firm in 2012, stepped down and was replaced by Allan Oberman, 59.

The company, which has a UK office in London, grew rapidly by snapping up other firms.

It now has a presence in more than 90 countries and sells more than 200 products.

For 2016, Concordia reported £616million turnover, adjusted profits of £353million, and debts of £2.8billion.